Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27777209 | 0.89 | ALDH1A1 (0.67) | ALDH1A1CYP3A4CYP2C19TSHRMMP8 | |
| SCHEMBL27798585 | 0.87 | CYP3A4 (0.58) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL1706030 | 0.85 | ALDH1A1 (0.73) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL627906 | 0.85 | ALDH1A1 (0.73) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL2846505 | 0.84 | GAA (0.68) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| Hydrochloric Acid SCHEMBL15063255 | 0.83 | ALDH1A1 (0.77) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL2841585 | 0.83 | NPY2R (0.51) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL28839977 | 0.81 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL6598560 | 0.81 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CYP2C19TSHRLMNA | |
| SCHEMBL15711320 | 0.81 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CYP2C19TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| CN-101679220-A | Histone deacetylase inhibitor | METHYLGENE INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2139850-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | ALDH1A1 532/4885CYP3A4 1017/4885CYP2C19 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.